ECSTACY: A Review of MDMA and MDA

Robert P. Climko · Herb Roehrich · Donald R. Sweeney · Jamil Al-Razi

78 citations0/0 files storedThe International Journal of Psychiatry in Medicine

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Psychedelics and Drug Studies Substance Abuse Treatment and Outcomes Forensic Toxicology and Drug Analysis

Abstract

The Drug Enforcement Administration classified the drug methylenedioxymethamphetamine, MDMA, also known as Ecstacy, as a Schedule I controlled substance on July 1, 1985. The controversy surrounding the classification of MDMA is related to the question of its efficacy as an adjunct to psychotherapy and the larger issue of how to regulate the production and use of designer drugs. The authors review the literature on MDMA and its predecessor, MDA, a substance that differs from MDMA by one methyl group.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 78 citations exist upstream.

References

1985Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals 1983Antagonism of the effects of the hallucinogen dom and the purported 5-HT agonist quipazine by 5-HT2 antagonists 1982Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes 2008Evaluation of 3,4-Methylenedioxyamphetamine (MDA) as an Adjunct to Psychotherapy

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.